Insperity reported third‑quarter 2025 revenue of $1.623 billion, a 4% increase from the same period last year, and a net loss of $20 million, translating to diluted earnings per share of $‑0.53. Adjusted earnings before interest, taxes, depreciation and amortization were $10 million, and adjusted earnings per share were $‑0.20. For comparison, the company posted adjusted EBITDA of $39 million and adjusted EPS of $0.39 in Q3 2024.
Gross profit fell 15% to $195 million, driven by a 9.1% rise in benefits costs versus Q3 2024. The increase was largely due to higher inpatient, outpatient and pharmacy utilization, as well as a higher frequency of large‑claim activity.
Insperity extended its UnitedHealthcare partnership through 2028, lowering the large‑claim pooling level to $500,000 effective January 1 2026. The extension is expected to reduce risk exposure and lower future claim costs.
The company also rolled out HRScale, a joint cloud‑based human‑capital‑management platform developed with Workday. Insperity invested $38 million in the partnership year‑to‑date, with a full‑year investment projected at approximately $58 million, positioning the firm to serve mid‑market clients.
Guidance for 2025 was revised downward. Full‑year adjusted earnings per share are now projected at $0.84 to $1.47, down from the prior range of $1.81 to $2.51. Adjusted EBITDA guidance was also reduced, and revenue guidance for the year is $5.1 billion, representing 0.5% to 3% growth over 2024.
Management emphasized continued focus on cost management and strategic initiatives aimed at stabilizing profitability in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.